Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Medicinal Chemistry
  4. Volume 32, Issue 6
  5. Article
Volume 32, Issue 6
  • ISSN: 0929-8673
  • E-ISSN: 1875-533X
file format text download EPUB
file format pdf download PDF
side by side viewer icon HTML

Abstract

Methylene blue (MB) has been routinely used to treat methemoglobinemia. In the body, MB is reduced to leucomethylene blue (LMB) by NADPH-dependent methemoglobin (MetHB) reductase, and then LMB reduces Fe3+ to Fe2+. In glucose-6-phosphate dehydrogenase (G6PD) deficiency, NADPH is not produced sufficiently to protect erythrocytes against oxidative stress and to take part in relevant biochemical reactions. Since MB is an oxidative agent, its administration in individuals with G6PD deficiency leads to an increased risk of hemolysis through oxidative stress and even death. Therefore, its administration has been prohibited from treating methemoglobinemia in G6PD patients. As an antioxidant and direct reducing agent for Fe3+, LMB may be prescribed for treating MetHB in patients with G6PD deficiency. Considering the biochemical process of turning MB into LBM and the reducing nature of LMB, it seems LMB is a safer drug than MB in treating methemoglobinemia. LMB can even be administrated in other treatments without any concern about increasing oxidative stress, exacerbating the inflammation. Proof-of-concept experimental and clinical trials could substantiate this hypothesis.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cmc/10.2174/0929867331666230911113159
2024-09-20
2025-04-23

  • From This Site

    /content/journals/cmc/10.2174/0929867331666230911113159
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/deliver/fulltext/cmc/32/6/CMC-32-6-01.html?itemId=/content/journals/cmc/10.2174/0929867331666230911113159&mimeType=html&fmt=ahah

References

  1. RosenP.J. JohnsonC. McGeheeW.G. BeutlerE. Failure of methylene blue treatment in toxic methemoglobinemia. Association with glucose-6-phosphate dehydrogenase deficiency.Ann. Intern. Med.1971751838610.7326/0003‑4819‑75‑1‑83 5091568
     [Google Scholar]
  2. Al-DubaiH. Al-MashdaliA. HailanY. Acute hemolysis and methemoglobinemia secondary to fava beans ingestion in a patient with G6PD deficiency.Medicine202110047e2790410.1097/MD.0000000000027904 34964759
     [Google Scholar]
  3. BarakaA.S. AyoubC.M. Yazbeck-KaramV. KaddoumR.N. GergesF.J. HadiU.M. DagherC.M. Prophylactic methylene blue in a patient with congenital methemoglobinemia.Can. J. Anaesth.200552325826110.1007/BF03016060 15753496
     [Google Scholar]
  4. RehmanA. ShehadehM. KhirfanD. JonesA. Severe acute haemolytic anaemia associated with severe methaemoglobinaemia in a G6PD-deficient man.Case Reports20182018223369
     [Google Scholar]
  5. BarravieraB. MachadoP.E.A. MeiraD.A. CuriP.R. MartinsJ.N.P. SouzaM.J. Glucose-6-phosphate dehydrogenase and glutathione reductase activity in methemoglobin reduction by methylene blue and cyst amine: Study on glucose-6-phosphate dehydrogenase-deficient individuals, on normal subjects and on riboflavin-treated subjects.Rev. Inst. Med. Trop. São Paulo198830537037810.1590/S0036‑46651988000500007 3249903
     [Google Scholar]
  6. HayesD.Jr Roessler-HendersonK.M. DavenportS.M. CollinsP.B. BallardH.O. Dyspnea in a lung transplant recipient.Respir. Care2010555626629 20420735
     [Google Scholar]
  7. McDonaghE.M. BautistaJ.M. YoungsterI. AltmanR.B. KleinT.E. PharmGKB summary.Pharmacogenet. Genomics201323949850810.1097/FPC.0b013e32836498f4 23913015
     [Google Scholar]
  8. LuzzattoL. Glucose 6-phosphate dehydrogenase deficiency: From genotype to phenotype.Haematologica2006911013031306 17018377
     [Google Scholar]
  9. FinielzP. GendooZ. LatasteA. ChuetC. GuiserixJ. Methemoglobinemia and intravascular hemolysis in a patient with G6PD deficiency.Nephron J.199262224224210.1159/000187048 1436328
     [Google Scholar]
  10. KimK-Y. TsaiF. CoyleW. SkinnerM. S2376 Indocyanine Green (ICG) is a safe alternative to methylene blue in patients with G6PD deficiency undergoing endoscopic submucosal dissection.Am. J. Gastroenterol.2020115S1263S1264
     [Google Scholar]
  11. BelfieldK.D. TichyE.M. Review and drug therapy implications of glucose-6-phosphate dehydrogenase deficiency.Am. J. Health Syst. Pharm.20187539710410.2146/ajhp160961 29305344
     [Google Scholar]
  12. BenchimolM. MadeiraL.B. de Oliveira-SouzaR. Late-life presentation of unsuspected G6PD deficiency.Case Rep. Crit. Care20182018819856510.1155/2018/8198565
     [Google Scholar]
  13. HassanK.S. Al-RiyamiA.Z. Al-HuneiniM. Al-FarsiK. Al-KhaboriM. Methemoglobinemia in an elderly patient with glucose-6-phosphate dehydrogenase deficiency: A case report.Oman Med. J.201429213513710.5001/omj.2014.33 24715943
     [Google Scholar]
  14. CappelliniM.D. FiorelliG. Glucose-6-phosphate dehydrogenase deficiency.Lancet20083719606647410.1016/S0140‑6736(08)60073‑2 18177777
     [Google Scholar]
  15. SumathipalaS. Glucose-6-phosphate dehydrogenase deficiency: A review. World Family Med. J.Middle East J. Family Med.2020189929710.5742/MEWFM.2020.93862
     [Google Scholar]
  16. YoungG.P. SmithM.B. WoodfieldD.G. Glucose-6-phosphate dehydrogenase deficiency in Papua New Guinea using a simple methylene blue reduction test.Med. J. Aust.197412287687810.5694/j.1326‑5377.1974.tb93397.x 4852168
     [Google Scholar]
  17. CliftonJ.II LeikinJ.B. Methylene blue.Am. J. Ther.200310428929110.1097/00045391‑200307000‑00009 12845393
     [Google Scholar]
  18. SikkaP. BindraV.K. KapoorS. JainV. SaxenaK.K. Blue cures blue but be cautious.J. Pharm. Bioallied Sci.20113454354510.4103/0975‑7406.90112 22219589
     [Google Scholar]
  19. LaslettN. HibbsJ. HallettM. GhaneieA. Zemba-PalkoV. Glucose-6-phosphate dehydrogenase deficiency-associated hemolytic anemia and methemoglobinemia in a patient treated with hydroxychloroquine in the era of COVID-19.Cureus2021135e1523210.7759/cureus.15232 34178542
     [Google Scholar]
  20. AlbertM. LessinM.S. GilchristB.F. Methylene blue: Dangerous dye for neonates.J. Pediatr. Surg.20033881244124510.1016/S0022‑3468(03)00278‑1 12891503
     [Google Scholar]
  21. WrightR.O. WoolfA.D. ShannonM.W. MagnaniB. N-acetylcysteine reduces methemoglobin in an in vitro model of glucose-6-phosphate dehydrogenase deficiency.Acad. Emerg. Med.19985322522910.1111/j.1553‑2712.1998.tb02617.x 9523930
     [Google Scholar]
  22. GreenbergM.I. Methylene blue.Emer. Med. News20012392610.1097/01.EEM.0000292322.94148.37
     [Google Scholar]
  23. LiuX. SpolaricsZ. Methemoglobin is a potent activator of endothelial cells by stimulating IL-6 and IL-8 production and E-selectin membrane expression.Am. J. Physiol. Cell Physiol.20032855C1036C104610.1152/ajpcell.00164.2003 12839837
     [Google Scholar]
  24. UmbreitJ. Methemoglobin-It’s not just blue: A concise review.Am. J. Hematol.200782213414410.1002/ajh.20738 16986127
     [Google Scholar]
  25. NatarajanM. JamesE. EbenezerK. EbenezerK. Methylene blue unresponsive methemoglobinemia.Indian J. Crit. Care Med.201418425325510.4103/0972‑5229.130582 24872659
     [Google Scholar]
  26. PanzaF. SolfrizziV. SeripaD. ImbimboB.P. LozuponeM. SantamatoA. ZeccaC. BarulliM.R. BellomoA. PilottoA. Tau-centric targets and drugs in clinical development for the treatment of Alzheimer’s disease.BioMed Res. Int.20162016324593510.1155/2016/3245935
     [Google Scholar]
  27. Hamidi AlamdariD. Bagheri MoghaddamA. AminiS. Hamidi AlamdariA. DamsazM. YarahmadiA. The application of a reduced dye used in orthopedics as a novel treatment against coronavirus (COVID-19): A suggested therapeutic protocol.Arch. Bone Jt. Surg.20208Suppl. 1291294 32607398
     [Google Scholar]
  28. Hamidi-AlamdariD. Hafizi-LotfabadiS. Bagheri-MoghaddamA. SafariH. MozdourianM. JavidarabshahiZ. Peivandi-YazdiA. Ali-ZeraatiA. SedaghatA. PoursadeghF. Barazandeh-AhmadabadiF. Agheli-RadM. TavousiS.M. VojouhiS. AminiS. AminiM. Majid-HosseiniS. Tavanaee-SaniA. GhiabiA. Nabavi-MahalliS. MorovatdarN. RajabiO. KoliakosG. Methylene blue for treatment of hospitalized COVID-19 patients: A randomized, controlled, open-label clinical trial, phase 2.Rev. Invest. Clin.202173319019810.24875/RIC.21000028 34019535
     [Google Scholar]
  29. MayJ.M. QuZ. CobbC.E. Reduction and uptake of methylene blue by human erythrocytes.Am. J. Physiol. Cell Physiol.20042866C1390C139810.1152/ajpcell.00512.2003 14973146
     [Google Scholar]
  30. FoltzL.M. DalalB.I. WadsworthL.D. BroadyR. ChiK. EisenhauerE. KobayashiK. KollmannsburgerC. Recognition and management of methemoglobinemia and hemolysis in a G6PD-deficient patient on experimental anticancer drug Triapine.Am. J. Hematol.200681321021110.1002/ajh.20547 16493607
     [Google Scholar]
  31. DalalB.I. KollmannsbergerC. Drug-induced haemolysis and methaemoglobinaemia in glucose 6-phosphate dehydrogenase deficiency.Br. J. Haematol.2005129329129110.1111/j.1365‑2141.2005.05404.x 15842651
     [Google Scholar]
  32. GauthierT.W. Methylene blue-induced hyperbilirubinemia in neonatal glucose-6-phosphate dehydrogenase (G6PD) deficiency.J. Matern. Fetal Med.20009425225410.1002/1520‑6661(200007/08)9:4<252::AID‑MFM14>3.0.CO;2‑U 11048840
     [Google Scholar]
  33. GoldenP.J. WeinsteinR. Treatment of high-risk, refractory acquired methemoglobinemia with automated red blood cell exchange.J. Clin. Apher.1998131283110.1002/(SICI)1098‑1101(1998)13:1<28::AID‑JCA6>3.0.CO;2‑B 9590495
     [Google Scholar]
  34. MullickP. KumarA. DayalM. BabbarS. KumarA. Aniline-induced methaemoglobinaemia in a glucose-6-phosphate dehydrogenase enzyme deficient patient.Anaesth. Intensive Care200735228628810.1177/0310057X0703500222 17444323
     [Google Scholar]
  35. MaddaliM.M. FahrJ. Postoperative methemoglobinemia with associated G-6-P-D deficiency in infant cardiac surgery - enigmas in diagnosis and management.Paediatr. Anaesth.200515433433710.1111/j.1460‑9592.2004.01420.x 15787927
     [Google Scholar]
  36. YangC-C. WuM-L. DengJ-F. Prolonged hemolysis and methemoglobinemia following organic copper fungicide ingestion.Vet. Hum. Toxicol.2004466321323 15587250
     [Google Scholar]
  37. Vadhan-RajS. FayadL.E. FanaleM.A. ProB. RodriguezA. HagemeisterF.B. Bueso-RamosC.E. ZhouX. McLaughlinP.W. FowlerN. ShahJ. OrlowskiR.Z. SamaniegoF. WangM. CortesJ.E. YounesA. KwakL.W. SarlisN.J. RomagueraJ.E. A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome.Ann. Oncol.20122361640164510.1093/annonc/mdr490 22015451
     [Google Scholar]
  38. KangS. Methaemoglobinaemia in a patient with G6PD deficiency: Case report.Reactions201214263
     [Google Scholar]
  39. BhatP. CollierA.B. Exchange transfusion as treatment for rasburicase induced methemoglobinemia in a glucose-6-phosphate dehydrogenase deficient patient.Pediatr. Blood Cancer200851456810.1002/pbc.21582
     [Google Scholar]
  40. KaradshehN.S. ShakerQ. RatroatB. Metoclopramide-induced methemoglobinemia in a patient with co-existing deficiency of glucose-6-phosphate dehydrogenase and NADH-cytochrome b5 reductase: Failure of methylene blue treatment.Haematologica2001866659660 11418378
     [Google Scholar]
  41. LiaoY-P. HungD-Z. YangD-Y. Hemolytic anemia after methylene blue therapy for aniline-induced methemoglobinemia.Vet. Hum. Toxicol.20024411921 11824767
     [Google Scholar]
  42. BilginH.; Özcan, B.; Bilgin, T. Methemoglobinemia induced by methylene blue pertubation during laparoscopy.Acta Anaesthesiol. Scand.199842559459510.1111/j.1399‑6576.1998.tb05173.x 9605379
     [Google Scholar]
  43. BalwaniM.R. BawankuleC.P. RamtekeV. TolaniP. VakilS. YadavR. Methylene blue induced methemoglobinemia with acute kidney injury in a glucose-6-phosphate dehydrogenase-deficient patient.Indian J. Nephrol.201727646546710.4103/ijn.IJN_316_16 29217886
     [Google Scholar]
  44. MüllerO. MockenhauptF.P. MarksB. MeissnerP. CoulibalyB. KuhnertR. BuchnerH. SchirmerR.H. Walter-SackI. SiéA. MansmannU. Haemolysis risk in methylene blue treatment of G6PD-sufficient and G6PD-deficient West-African children with uncomplicated falciparum malaria: A synopsis of four RCTs.Pharmacoepidemiol. Drug Saf.201322437638510.1002/pds.3370 23135803
     [Google Scholar]
  45. ShimJ-Y. SeoY-S. YangJ-O. LeeE-Y. HongS-Y. GilH-W. A fatal case of methylene blue threatment failure in methemoglobinemia.J. Korean Soc. Clin. Toxicol.200642151154
     [Google Scholar]
  46. MandiG. WitteS. MeissnerP. CoulibalyB. MansmannU. RengelshausenJ. SchiekW. JahnA. SanonM. WüstK. Walter-SackI. MikusG. BurhenneJ. RiedelK.D. SchirmerH. KouyatéB. MüllerO. Safety of the combination of chloroquine and methylene blue in healthy adult men with G6PD deficiency from rural burkina faso.Trop. Med. Int. Health2005101323810.1111/j.1365‑3156.2004.01356.x 15655011
     [Google Scholar]
  47. MüllerO. MeissnerP. MansmannU. Glucose-6-phosphate dehydrogenase deficiency and safety of methylene blue.Drug Saf.20123518510.2165/11597790‑000000000‑00000 22149420
     [Google Scholar]
  48. MeissnerP.E. MandiG. WitteS. CoulibalyB. MansmannU. RengelshausenJ. SchiekW. JahnA. SanonM. TapsobaT. Walter-SackI. MikusG. BurhenneJ. RiedelK.D. SchirmerH. KouyatéB. MüllerO. Safety of the methylene blue plus chloroquine combination in the treatment of uncomplicated falciparum malaria in young children of Burkina Faso. [ISRCTN27290841].Malar. J.2005414510.1186/1475‑2875‑4‑45 16179085
     [Google Scholar]
  49. YoungsterI. ArcaviL. SchechmasterR. AkayzenY. PopliskiH. ShimonovJ. BeigS. BerkovitchM. Medications and glucose-6-phosphate dehydrogenase deficiency: An evidence-based review.Drug Saf.201033971372610.2165/11536520‑000000000‑00000 20701405
     [Google Scholar]
  50. TanenD.A. LoVecchioF. CurryS.C. Failure of intravenous N-Acetylcysteine to reduce methemoglobin produced by sodium nitrite in human volunteers: A randomized controlled trial.Ann. Emerg. Med.200035436937310.1016/S0196‑0644(00)70056‑4 10736124
     [Google Scholar]
  51. KuwadaG. MurakamiA. GlaserD.W. IngrahamS.E. PurohitP.J. Mothball Ingestion in the setting of G6PD deficiency causing severe hemolytic anemia, methemoglobinemia, and multiple organ failure in a toddler.Hawaii J. Health Soc. Welf.202281135 35028588
     [Google Scholar]
/content/journals/cmc/10.2174/0929867331666230911113159
Loading
The Potential of Leucomethylene Blue in Methemoglobinemia Treatment: A New Hope for Patients with G6PD?
Curr. Med. Chem. 32, 1033 (2025); https://doi.org/10.2174/0929867331666230911113159
/content/journals/cmc/10.2174/0929867331666230911113159
/content/journals/cmc/10.2174/0929867331666230911113159
Loading

Data & Media loading...


  • Article Type:     Editorial
Keyword(s): G6PD deficiency; hemolysis; Leucomethylene blue; methemoglobinemia; methylene blue; oxidative stress

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test